ArticleFrontiers in medicine2026
Analysis of risk factors compromising embryo quality and quantity in patients with endometriosis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to analyze the clinical factors affecting embryo quality and quantity in endometriosis patients undergoing Methods: Univariate logistic regression was performed to select variables ( Results: The model demonstrated robust discriminative ability, with area under the curve values of 0.765 (95% CI: 0.749-0.769) in the training set and 0.776 (95% CI: 0.747-0.789) in the validation set. Subgroup analyses further revealed that endometriomas represent a pivotal phenotype adversely affecting both the yield of oocytes and the rate of high-quality embryos. Conclusion: Anti-Müllerian Hormone level, Antral Follicle Count, the presence of bilateral endometriomas, and the utilization of gonadotropin-releasing hormone (GnRH) agonist pre-treatment serve as robust indicators for predicting oocyte yield in patients with endometriosis. The nomogram incorporating these factors provides a practical tool for the early prognostication of ovarian response, thereby offering valuable insights for formulating personalized treatment strategies. GnRH agonist administration demonstrates efficacy in improving clinical outcomes of IVF/ICSI cycles in these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.